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ABSTRACT
The development of multi-target drugs and irreversible modulators of deregulated 
signalling proteins is the major challenge for improving glioblastoma multiforme 
(GBM) treatment. Reversible single-target drugs are not sufficient to sustain a 
therapeutic effect over time and may favour the activation of alternative signalling 
pathways and the onset of resistance phenomena. Thus, a multi-target compound 
that has a long-lasting mechanism of action might have a greater and longer life 
span of anti-proliferative activity. Recently, a dual-target indol-3ylglyoxyldipeptide 
derivative, designed to bind to the Translocator Protein (TSPO) and reactivate p53 
function via dissociation from its physiological inhibitor, murine double minute 2 
(MDM2), has been developed as a potent GBM pro-apoptotic agent. In this study, 
this derivative was chemically modified to irreversibly bind MDM2 and TSPO. The 
new compound elicited a TSPO-mediated mitochondrial membrane dissipation and 
restored p53 activity, triggering a long-lasting apoptosis of GBM cells. These effects 
were sustained over time, involved a stable activation of extracellular signal regulated 
kinases and were specifically observed in cancer cells, in which these protein kinases 
are deregulated. Dual-targeting and irreversible binding properties combined in the 
same molecule may represent a useful strategy to overcome the time-limited effects 
elicited by classical chemotherapies.
INTRODUCTION
Glioblastoma multiforme (GBM), a WHO grade 
IV malignant glioma [1], is the most common and lethal 
primary brain tumour in adults [2], with a median survival 
of less than 2 years. Presently, treatment of GBM is based 
on cytoreductive resection combined with radiotherapy 
and adjuvant chemotherapy with Temozolomide (TMZ) 
[3]. Nonetheless, the prognosis of GBM patients remains 
poor because of the onset of drug resistance and tumour 
recurrence [4, 5]. A number of attempts have been made 
to understand the molecular basis of resistance, and 
consequently, different approaches have been tried to 
overcome this phenomenon such as the use of multi-target 
drugs and the trial of long-lasting active molecules [6]. 
Recent discoveries in molecular biology have shown 
that the aberration of different signalling pathways are 
involved in the pathogenesis of malignant gliomas and 
have allowed the identification of new targets for novel 
therapeutic approaches, including growth factor ligands, 
receptors, and intracellular downstream effectors [7]. 
Because these deregulated intracellular signalling 
pathways, including the PI3K/Akt/mammalian target of 
the rapamycin (mTOR) and the Ras/extracellular signal-
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regulated kinase (ERK), are a point of convergence for 
different stimuli, the concept of one disease-one drug is 
challenging, and multi-target therapy is becoming the 
favourite way to develop innovative and more efficient 
therapies [8-11].
Furthermore, it has been postulated that reversible 
drugs may have several limitations in cancer therapy. 
Indeed, a reversible molecule may not be enough to 
sustain a therapeutic effect over time, thereby favouring 
the activation of alternative signalling pathways that 
escape drug action and cause resistance. For these 
reasons, oncology research has recently been focused 
on the synthesis and development of new irreversible 
and long-lasting molecules [12]. Recently, different 
irreversible inhibitors for tyrosine kinase receptors have 
been described, and some of these are under clinical 
development for the therapy of breast, lung and other 
solid tumours [13-18]. Lately, pre-clinical results for an 
irreversible, orally administered pan-ERBB inhibitor in 
mice GBM xenograft tumours have been reported [19]. 
These data showed that the long-lasting activity of the drug 
towards epidermal growth factor receptor (EGFR) can 
substantially increase the efficacy of the drug, suggesting 
irreversible ligands as a new, valuable therapeutic option 
to overcome drug resistance.
In GBM, p53 and Translocator protein (TSPO), 
both acting as apoptosis inducers, represent two attractive 
intracellular targets. Classic TSPO ligands, such as 
PK11195, have demonstrated anticancer effects both in 
vitro and in vivo; in addition, newly synthesized TSPO 
ligands triggered apoptosis in human and rat GBM cells by 
modulating the opening of the mitochondrial permeability 
transition pore (MPTP), of which TSPO is an important 
constitutive protein [20, 21].
On the other hand, deregulation of the p53 protein 
is widely described in the literature, and reactivation of its 
endogenous function represents an important anticancer 
therapeutic strategy, at least for those tumours that do 
not contain a mutant p53. P53 is negatively regulated by 
the murine double minute 2 (MDM2), and inhibitors of 
MDM2/p53 interaction currently represent another viable 
approach in GBM therapy [22-24].
Recently, we have characterized TSPO/MDM2 
dual-target ligands and demonstrated that these agents 
present an attractive multi-modal anti-cancer activity in 
GBM cells [25]. In this study, we started from this scaffold 
and synthesized a new dual target compound with long-
lasting binding properties towards MDM2 and TSPO. 
Specifically, this compound was characterized by the 
presence of a chemo-reactive isothiocyanate group, able 
to covalently bind the target proteins. The compound 
activated mitochondrial membrane dissipation and 
restored p53 activity, inducing GBM cell apoptosis. It is 
noteworthy that the new molecule oriented the cellular fate 
towards irreversible apoptosis via the stable activation of 
the p53-MDM2-ERK axis. These results indicated that 
the development of new molecules targeting more key 
proteins and able to regulate intracellular signalling over 
time may offer innovative and alternative strategies to 
overcome the reversible activity of chemotherapy agents.
RESULTS
Synthesis of the new compound
The convergent procedure applied for the 
synthesis of the target indole derivative EB148 is 
outlined in Figure 1. The dipeptide 3 was obtained 
in two steps starting from Boc-L-leucine 1, which 
was condensed with L-phenylalanine ethyl ester in 
the presence of N,N’-carbonyldiimidazole (CDI) in 
anhydrous dimethylformamide to obtain compound 2, 
then deprotected by treatment with trifluoroacetic acid, 
as previously described [25]. Acylation of the 5-nitro-
2-phenylindole 5 with oxalyl chloride in anhydrous 
ethyl ether at 0°C yielded the corresponding 5–nitro-2-
phenylindolylglyoxylyl chloride 6 [26].
Reaction of derivative 6 with compound 3 in 
the presence of triethylamine in anhydrous toluene at 
0°C gave compound 7, which was purified by flash 
chromatography. Then, the (5-nitro-2-phenylindol-3-yl)
glyoxyl-L-leucine-L-phenylalanine ethyl ester 7 was 
catalytically hydrogenated over palladium to yield the 
corresponding amine 8, which was then reacted with 
thiophosgene in a biphasic CH2Cl2/aqueous NaHCO3 
solution to give the desired isothiocyanato derivative 
Table 1: Kinetic binding parameters of various compounds at human TSPO.
Compound Kon (M-1 min-1) Koff (min-1)  t1/2 pKd pKi (nM)
PK11195a 9.15 ± 0.85 x 106 0.0264 ± 0.0018 26.1 ± 1.8 2.89 x 10
-9
2.88 ± 0.13
EB54 2.16 ± 0.31 x 105 0.0289 ± 0.0031 23.9 ± 2.6 134 x 10-9 108 ± 10
EB148 3.21 ± 0.35 x 10
5
0.004809 ± 0.00059 144 ± 5 150 x 10-9 199 ± 18
a All the kinetic data were obtained from competition kinetic studies, with the exception of [3H] PK11195 that was obtained 
through direct association and dissociation measurements (Figure 1). Data represent the mean ± SEM of three different 
experiments.
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EB148, which was purified by flash chromatography. The 
reversible analogue EB54 was synthesized essentially as 
described previously [25]. Purity degree of the compounds 
(> 96%) was assessed by HPLC.
The stability of EB148 in aqueous solution was 
evaluated by HPLC analysis. The results showed no 
significant degradation of the compound: indeed, the 
average peak area of EB148 was 98.83 ± 0.47 % within 
72 h. 
EB148 exhibited long-lasting binding properties 
to TSPO
At first, the ability of EB148 to bind human TSPO 
was tested by radioligand binding studies in U87MG cells. 
EB54 and EB148 (Figure 2A) displaced specific [3H]
PK11195 binding in a concentration-dependent manner, 
with Ki values of 108 ± 10 nM and 199 ± 18 nM (Figure 
2B), respectively. The affinity of the reversible ligand 
(EB54) towards human TSPO was consistent with data 
obtained in rat kidney membranes [25].
Direct kinetic binding studies indicated that [3H]
PK11195 labelled TSPO with an association constant rate 
(Kon) of 9.15 ± 0.85 x 106 M-1 min-1 (Figure 2C; Table 
1). Dissociation occurred rapidly when the ligand-receptor 
complex was exposed to a saturating concentration of 
unlabelled PK11195 (Figure 2C). The dissociation rate 
constant (Koff) was estimated to be 0.0264 ± 0.0018 min-
1, leading to a calculated half-life of 26.1 ± 1.8 min-1. 
One of the advantages of long-lasting inhibitors 
Figure 1: Synthesis of the new derivative EB148. 
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is the sustained inhibition of the target protein, with a 
recovery of activity that occurs only after re-synthesis 
of the target protein. To determine the binding kinetics 
of EB54 and EB148, a competition kinetic method was 
performed [27,28]. Figure 3 shows the effect of multiple 
concentrations of unlabelled test compounds on the 
association binding kinetics of [3H]PK11195. By fixing 
the association and dissociation rate constants for [3H]
PK11195 to the values previously determined, it was 
possible to obtain the relevant kinetic binding parameters 
for each compound (Table 1). 
The rank order of dissociation half-lives for the 
tested compounds was EB148 > PK11195 ≥ EB54, thus 
demonstrating that EB148 acts as a long-lasting TSPO 
ligand. To verify the kinetic approach, the pKd values for 
the tested ligands were calculated as a ratio of estimated 
koff and kon values. The comparison between pKd 
and competition pKi values (Table 1 and Figure 2B) 
demonstrates that the two methods produce comparable 
results, thus validating the indirect kinetic method. 
EB148 induced a sustained membrane potential 
dissipation
Several pieces of evidence have shown that TSPO 
is a constituent of the MPTP and therefore takes part in 
the dissipation of membrane potential (Δψm) that occurs 
after MPTP opening. To assess whether the compounds 
could modulate MPT-pore opening through their selective 
binding to TSPO, Δψm was measured in mitochondria 
isolated from U87MG cells. The treatment of the isolated 
mitochondria with EB54 or EB148 (1 µM) for 20 min led 
to a significant reduction in tetrachloro-tetraethylbenzimid
azolylcarbocyanine iodide (JC-1) accumulation compared 
to control untreated mitochondria, demonstrating 
the collapse of Δψm (Figure 4A, 4B and 4C). When 
compound-treated mitochondria were centrifuged and 
washed to remove the TSPO ligands, only EB148 
determined Δψm collapse. These results demonstrate that 
the long-lasting TSPO ligand can dissipate Δψm even after 
mitochondria wash-out (Figure 4B and 4C).
Figure 2: Affinity to TSPO in [3H]PK11195 radioligand binding assay. A. Chemical structures of EB54 and EB148. B. U87MG 
cell membranes (20 µg of proteins) were incubated with 1.5 nM [3H]PK11195 and different compound concentrations. After reaching 
equilibrium, samples were filtered and bound radioactivity was counted. Data are expressed as a percentage of specific binding versus the 
basal value (set to 100%) and represent the mean ± SEM of three different experiments. C. Kinetics binding profile of [3H]PK11195 to 
TSPO. U87MG cell membranes (20 μg protein) were incubated with 1.5 nM radioligand at various times up to 3 h. Dissociation kinetics 
were determined by pre-equilibrating membranes and [3H]PK11195 for 180 min; a saturating concentration of cold PK11195 (1 μM) was 
then added at various times. Association and dissociation data are expressed as percentage of maximum specific binding, and globally fit 
using Prism 5.0. Data represent the mean ± SEM of three different experiments.
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EB148 induced a long-lasting dissociation of p53-
MDM2 complex
The activity of EB148 in inhibiting MDM2-p53 
complex was assessed using a validated assay [25, 29]. 
The compound was able to efficaciously dissociate 
the MDM2-p53 complex with an IC50 of 6.81 ± 0.79 
nM (Figure 5A), a value comparable to that obtained 
with the reversible analogue EB54 [25]. The effect of 
the compound, tested at three different concentrations, 
Figure 3: Competition kinetics curves for [3H]PK11195 binding to TSPO-expressing membranes. U87MG cell membranes 
(20 μg protein) were incubated with 1.5 nM radioligand at various times in the presence of increasing concentrations of EB54 or EB148. 
Data are expressed as [3H]PK11195 specific bound (dpm) and are representative of at least three independent experiments, each performed 
in duplicate. 
Figure 4: Evaluation of Δψm in isolated mitochondria. Mitochondria (5 µg of proteins) were treated with DMSO, EB54 or 
EB148 for 20 min. In wash-out experiments, mitochondria were then centrifuged at 11.000 x g for 5 min, washed with fresh saline and 
suspended in JC-1 buffer not containing the drugs. The Δψm was evaluated using the JC-1 protocol as described in the Methods section. A., 
B. Representative graph of mitochondria potential evaluation using the JC-1 protocol. The results were expressed as RFU units in time. C. 
The data are expressed as variation of JC1 uptake into mitochondria, calculated as the difference between the RFU read after 10 minutes and 
the RFU read at the beginning, and represent the mean value ± SEM of three different experiments. Statistical significance was determined 
with a one-way ANOVA with a Bonferroni post-test: **p<0.01, ***p<0.001 vs. control; ##p<0.01 vs. EB54-treated cells. 
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appeared to be time and concentration dependent, with a 
half-life (t1/2) of 16.4 ± 2.1 (10 nM), 3.83 ± 0.65 (100 nM) 
and 2.27 ± 0.93 (10 µM) min-1, respectively. No significant 
differences in the association kinetics between EB54 
and EB148, both tested at a 10 µM concentration, were 
detected (EB54: t1/2=2.33 ± 0.83; Figure 5B).
To verify the EB148 covalent mechanism of 
action, kinetic dissociation of the p53/MDM2 complex 
was evaluated in cell lysates and in whole cells. Cell 
lysates were treated for 60 min with EB148 or EB54 
at a concentration ten-fold higher than their IC50 value. 
Afterwards, the lysates were diluted 1:20 by adding 
reaction buffer and incubated for different times (0-180 
min), after which the extent of p53-MDM2 complex was 
quantified. The activity of compound EB148 in inhibiting 
p53-MDM2 complex was maintained unchanged after 
sample dilution. In contrast, the reversible analogue 
gradually decreased its activity through the dilution time 
(Figure 6A and 6B). These data confirmed that EB148 acts 
as a long-lasting inhibitor of the p53-MDM2 complex. 
Figure 5: Affinity and association kinetics of EB148 towards MDM2. A. U87MG cell lysates containing the native MDM2/
p53 complex were pre-incubated with DMSO (control) or different concentrations of EB54 or EB148 for 15 min. Then the lysates were 
captured on wells pre-coated with MDM2 antibody. After extensive washing, the levels of the MDM2/p53 complex were quantified using 
an antibody specific for p53 and subsequently an HRP-conjugated antibody and a TMB substrate kit. Blank wells were obtained in the 
absence of p53 antibody. Data are expressed as a percentage of control set to 100%, and represent the mean ± SEM of three independent 
experiments. B. U87MG cell lysates containing the native MDM2/p53 complex were pre-incubated with DMSO (control) or the indicated 
concentrations of EB148 or EB54 for different times (0-120 min). Following incubation, the lysates were captured on wells pre-coated with 
MDM2 antibody and levels of the MDM2/p53 complex were quantified as in A. Curves were generated using a sigmoidal dose-response 
curve model (A) (GraphPad Prism 5 software) from which the IC50 values were derived, or an association kinetics model (B).
Figure 6: Dissociation Kinetics from MDM2. (A., B.) Cell lysates containing the native MDM2/p53 complex were pre-incubated 
with DMSO (control) or the indicated concentrations of EB148 or EB54 for 120 min, to reach an association plateau. Dissociation was 
initiated by the addition of 20 volumes of cold buffer and the lysates were further incubated at 4°C for the indicated times (0-180 min). 
Following incubation, 200 µl of the mixture were captured on wells pre-coated with MDM2 antibody. After extensive washing, the levels 
of the MDM2/p53 complex were quantified using an antibody specific for p53 and subsequently an HRP-conjugated antibody and a TMB 
substrate kit. Data are expressed as a percentage of control set to 100% and represent the mean ± SEM of three independent experiments. 
Curves were generated using a dissociation kinetics model (GraphPad Prism 5 software).
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A limitation of the “in tube” assay is that it is an 
isolated system that does not account for compound 
permeability through the cell membrane as well as the 
cellular machinery that may interfere with the biological 
activity by regulating the expression/degradation of 
protein target and of the compound itself. For this reason, 
the activity of EB148 or EB54 as inhibitors of the p53-
MDM2 complex was also assessed in whole cells using 
the same validated ELISA assay. U87MG cells were 
incubated for 8 h with EB148 or EB54 and then the levels 
of the p53-MDM2 complex were quantified. As expected, 
both EB54 and EB148 inhibited the p53-MDM2 complex 
after 8 h (Figure 7). When U87MG cells were washed out 
to remove ligands, a significant difference in the recovery 
of p53-MDM2 complex formation was observed. As 
shown in Figure 7, in cells treated with EB54, the recovery 
of p53-MDM2 complex occurred within 12 h. The long-
lasting compound EB148 significantly slowed down new 
complex formation, which was maintained significantly 
lower than in the control even after 24 h cell wash-out 
(Figure 7).
EB148 efficiently reactivated the p53 pathway
To support the reactivation of the p53 pathway, 
mRNA expression levels of p53 target genes and p53 
protein expression were evaluated. Significant differences 
in the kinetics of induction of p53 target genes were 
detected after cell incubation with the long-lasting MDM2 
inhibitor EB148 or the reversible analogue EB54. Indeed, 
after 8 and 16 h of U87MG cell treatment EB54 induced 
a significant increase in the mRNA expression level of 
p21, p53 and MDM2 (Figure 8A and 8B). The expression 
of these genes gradually slowed down and, after 24 h, 
reached values significantly lower than controls (Figure 
8C), likely by means of a feed-back inhibition mechanism. 
In contrast, EB148 induced a sustained increase in 
the mRNA expression of p53 target genes up to 24 h of 
cell treatment. Notably, high induction of MDM2 mRNA 
was observed: EB148 caused a 6.9-, 8.8- and 2.2-fold 
induction of MDM2 mRNA after 8, 16 and 24 h of cell 
treatment, respectively, whereas the maximal increase 
of the MDM2 transcript elicited by EB54 was 2.9-fold 
versus control (Figure 8A, 8B and 8C). To evaluate 
reversible versus long-lasting effects of EB54 and EB148, 
cells were treated with each compound for 2 h and then 
washed out for 16 h in a drug-free medium. After the cells 
were challenged with EB54, the levels of the p53 target 
genes were down-regulated (Figure 8D). When the long-
lasting compound EB148 was added in the pre-incubation 
medium, the transcripts of p53 target genes returned to 
control values (Figure 8D).
Consistent with the data obtained with Real time 
PCR analysis (RT-PCR), challenging GBM cells with 
EB54 and EB148 for 16 h led to a slight but significant 
increase in p53 protein levels (Figure 9A and 9B); a wash-
out period of 16 h brought p53 accumulation to control 
levels in EB54-treated cells. In contrast, even if the 
transcription was not activated at this time point, EB148 
also maintained high p53 levels after cell wash-out (Figure 
9A and 9B).
EB148 induced a long-lasting activation of 
intracellular ERK
The kinetic pattern of ERK activation is the pre-
requisite that regulates the final biological outcomes of 
these kinases. A transient kinase activation is commonly 
associated with a proliferative effect, whereas their 
sustained phosphorylation over time triggers death 
signalling pathways. In this regard, the kinetics of ERK 
activation induced by EB148 and its reversible analogue, 
EB54, were evaluated. The data depicted in Figure 10A 
and 10B showed that reversible compound EB54 did not 
induce any significant ERK1/2 stimulation. In contrast, 
EB148 induced significant ERK phosphorylation, and 
this signal remained switched-on up to 8 h after cell 
treatment (Figure 10A). Moreover, after cell wash-out the 
long lasting compound EB148 continued to significantly 
activate the MAPKs (Figure 10A).
To unequivocally prove that ERK activation elicited 
by EB148 was mediated by p53, experiments were 
repeated in the presence of the p53 inhibitor pifithrin-β 
(1 µM) [30].
As depicted in Figure 10B, blocking p53 completely 
impaired EB148-mediated ERK1/2 activation but did 
not significantly affect the EB54 response. These data 
demonstrate that the sustained ERK1/2 phosphorylation 
elicited by the long-lasting MDM2 inhibitor involves a 
p53-mediated mechanism.
It has been ascertained that a sustained activated 
ERK directly interacts with MDM2 inhibiting its ubiquitin 
ligase activity and triggering pro-apoptotic p53-mediated 
pathways [31,32]. To evaluate the role of ERK in the 
long-lasting effects evoked by EB148, the association 
between ERKs and MDM2 in response to cell treatment 
with EB148 was evaluated. EB148 induced a significant 
and marked induction of complex formation (Figure 10C). 
This association was evident after both 8 and 24 h after 
cell treatment and remained significant after cell wash-out 
for 24 h. These data suggest that the long-lasting inhibition 
of MDM2 induced sustained ERK phosphorylation, and 
this activated kinase might play a role in controlling 
MDM2 activity and triggering p53-mediated apoptotic 
effects. In contrast, cell incubation with EB54 did not 
induce any significant MDM2-ERK association.
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Figure 7: Levels of p53/MDM2 complex in U87MG whole cells. U87MG cells were treated with DMSO (control), 1 µΜ EB148 
or 1 µΜ EB54 for 8 h; when indicated, cells were washed-out for 12-24 h to remove the drugs. At the end of the treatments, the cells were 
collected and lysed; the quantification of p53/MDM2 complexes in U87MG cells was assessed by the ELISA method as described above. 
Data are expressed as percentage of control set to 100%, and represent the mean ± SEM of three independent experiments. The significance 
of the differences was determined with a one-way ANOVA with a Bonferroni post-test: * p<0.05, ** p<0.01, *** p<0.001 vs. control; # 
p<0.05, ### p<0.001 vs. cells treated for 8 h.
Figure 8: Effects of the MDM2 inhibitors on the reactivation of p53 pathway. U87MG cells were treated with DMSO 
(control), or 1 µΜ EB148 or 1 µΜ EB54 for 8 h A., 16 h B., or 24 h C. Aliquots of cells, after treatment with the compounds for 16 h, were 
washed-out for additional 16 h in drug-free medium D. At the end of the treatment period, the relative mRNA quantification of p53 target 
genes (p53, p21 and MDM2) was performed by real-time RT-PCR as described in the Methods section. The data are the mean values ± SEM 
of three different experiments, each performed in duplicate. The significance of the differences was determined with a one-way ANOVA 
with a Bonferroni post-test: * p<0.05, ** p<0.01, *** p<0.001 vs. control.
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Figure 9: Effects of the MDM2 inhibitors on p53 protein accumulation. U87MG cells were treated with DMSO (control), or 1 
µM EB148 or 1 µΜ EB54 for 16 h, followed by a wash-out period of an additional 16 h. At the end of the treatment, p53 protein levels were 
evaluated by western blotting analysis using GAPDH as the loading control. A. Representative western blots. B. Densitometric analysis of 
the immunoreactive bands performed using the ImageJ program. The data were expressed as the percentage relative to control, and they are 
the mean values ± SEM of three different experiments. The significance of the differences was evaluated using a one-way ANOVA with the 
Bonferroni post-test: *p<0.05, **p<0.01 vs. control.
Figure 10: ERK phosphorylation and levels of ERK/MDM2 complex in U87MG cells. A. U87MG cells were treated with 
DMSO (control), 1 µΜ EB148 or 1 µΜ EB54 for the indicated times; in some experiments, after 2 h of treatment the medium was replaced 
by fresh medium not containing drugs for an additional 2 h. At the end of the treatment period the levels of ERK 1/2 phosphorylation were 
evaluated using ELISA kits, as described in the Methods section. The data are expressed as the percentage of phosphorylated ERK1/2 
versus untreated cells (control), which were set at 100%. Data are the mean values ± SEM of three independent experiments performed 
in triplicate. Analysis of significant differences in mean ERK/MDM2 complex levels was performed using one-way ANOVA with a 
Bonferroni post-test: * p< 0.05, ** p< 0.01, *** p<0.001 vs. control. B. U87MG cells were treated for 30 min with DMSO (control) or the 
p53 inhibitor, pifithrin-β (1 µΜ); subsequently, cells were incubated with DMSO, EB148 or EB54 1 µM for 2 h. At the end of the treatment 
periods, the levels of ERK 1/2 phosphorylation were evaluated using ELISA kit, as in A. The significance of differences was performed 
using one-way ANOVA with a Bonferroni post-test: * p< 0.05 vs. control; #p<0,05 vs. cells not treated with the p53 inhibitor. C. U87MG 
cells were treated with DMSO (control), 1 µΜ EB148 or 1 µΜ EB54 for the indicated times; in some experiments, after 8 h of treatment, 
the medium was replaced by fresh medium not containing drugs for an additional 24 h. At the end of the treatment period, U87MG cells 
were collected and suspended in lysis buffer. Equal amounts of cell lysates were captured on wells pre-coated with MDM2 antibody. After 
extensive washing, the levels of the ERK/MDM2 complex were quantified using an antibody specific for ERKs, and subsequently an HRP-
conjugated antibody and a TMB substrate kit. Data are expressed as percentage of control set to 100%, and represent the mean ± SEM of 
three independent experiments. The significance of the differences was determined with a one-way ANOVA with Bonferroni post-test: * 
p<0.05, ** p<0.01, *** p<0.001 vs. control.
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EB148 inhibited GBM cell proliferation over time 
and triggered apoptosis
The effects of the compounds on cell viability 
and proliferation were then examined. Cell treatment 
with EB54 or EB148 for 72 h induced a concentration-
dependent reduction in cell proliferation, yielding IC50 
values of 177 ± 15 nM and 91.6 ± 8.9 nM, respectively 
(Figure 11A). Moreover, both compounds reduced the 
total number of living cells, showing a maximal effect at 
100 µM concentration (Figure 11B). 
To assess whether U87MG cells could resume 
growing after inhibitor removal, culture medium was 
replaced with fresh medium not containing drugs and 
cell proliferation was monitored 72 h after cell wash-
out. After EB148 cell treatment and subsequent removal, 
the inhibition of cell proliferation was maintained, thus 
suggesting the inability of the cells to restart proliferation. 
In contrast, a significant recovery in proliferative activity 
was detected when cells were pre-treated with the 
reversible compound EB54 (Figure 11C). These results 
suggest that the drug-target residence time plays a crucial 
role in the control of cell proliferation over-time.
To determine toxicity in non-tumour cells, the 
effects of EB148 and EB54 were examined on normal 
mesenchymal Stem Cells (MSCs) isolated from human 
bone marrow. Of note, the MSC viability of non-cancer 
cells was significantly decreased after 72 h of incubation 
with EB54 at 10 µM (Suppl. Figure 1). However, 
the percentages of cell proliferation reduction were 
significantly lower than those observed in U87MG cells, 
Figure 11: Effects of the MDM2 inhibitors on U87MG cell proliferation/viability. A. U87MG cells were treated in complete 
medium with the indicated concentrations of EB148 or EB54 for 72 h. At the end of treatment, cell proliferation was measured using the 
MTS assay. The data are expressed as a percentage versus untreated cells (control), which was set to 100%, and are the mean values ± 
SEM of three independent experiments, each performed in duplicate. Curves were generated using a sigmoidal dose-response curve model 
(GraphPad Prism 5 software) from which the IC50 values were derived. B. U87MG cells were treated as in A; live and dead cells were then 
estimated using the trypan blue exclusion test. The data are expressed as number of living or dead cells per well and are the mean values 
± SEM of two independent experiments, each performed in triplicate. * p<0.05, ** p<0.01, *** p<0.001 vs. control live cells; #p<0.05 vs. 
control dead cells. C. U87MG cells were treated with the indicated concentrations of EB148 or EB54 for 72 h, and then, the medium was 
replaced with drug-free fresh medium for additional 72 h. At the end of the treatment period, cell viability was measured using the MTS 
assay. The data are expressed as a percentage versus untreated cells (control), which was set to 100% and are the mean values ± SEM of 
three independent experiments, each performed in duplicate. The significance of the differences was determined with a one-way ANOVA 
with a Bonferroni post-test: *** p<0.001 vs. control; #p<0.05 vs. cells treated for 72 h.
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suggesting that the anti-proliferative effect elicited by the 
reversible dual ligand EB54 was directed preferentially 
towards tumour cells. In contrast, EB148 did not affect 
MSC proliferation even at the highest concentration tested, 
suggesting a lack of cell toxicity. 
Then, the effect of EB148 on the regulation of cell 
cycle and on the apoptotic process was investigated. P53 
activation in proliferating cells often caused cell cycle 
arrest at the G1 or G2 phases, an event that commonly 
involves the cyclin-dependent kinase inhibitor p21. 
According to these outcomes, a cell cycle cytofluorimetric 
assay revealed that both compounds similarly induced a 
significant increase in G0/G1 phase, suggesting a block of 
the cell cycle (Figure 12A and 12B).
In addition, the treatment of U87MG cells with 
EB148, as well as with the reversible EB54, induced 
a significant phoshpatidilserine externalization in the 
absence and in the presence of 7-amino-actinomysin 
binding to DNA, thus demonstrating that both compounds 
induced early and late apoptosis of the cells (Figure 12C 
and 12D).
DISCUSSION
Compound EB148, designed as a dual molecule 
targeting both MDM2 and TSPO proteins, was 
demonstrated in this study to activate the ERK intracellular 
signalling pathway over time, driving GBM cells towards 
an unavoidable fate of death. These effects were also 
maintained after ligand depletion, thus suggesting that 
increasing the drug-residence time to its targets may 
Figure 12: Effects of the MDM2 inhibitor on U87MG apoptosis and cell cycle. A., B. U87MG cells were treated for 24 h with 
DMSO (control), or 1 µM EB148 or 1 µΜ EB54. At the end of the treatment period, the cell cycle was analysed as described in the Methods 
section. Representative cell cycle histograms of untreated and treated cells are shown in A. The data are expressed as the percentage of cells 
in the different phases (G0/G1, G2 or S) versus the total cell number and are the mean values ± SEM of three different experiments. The 
significance of the differences was determined with a one-way ANOVA with Bonferroni post-test: * p<0.05 vs. control in the respective 
cellular phase. C., D.) U87MG cells were treated as in A. At the end of the treatment period, the cells were collected, and the level of 
phosphatidylserine externalisation was evaluated using the Annexin V-staining protocol, as described in the Methods section. D. The data 
are expressed as the percentage of apoptotic cells (the data for the early-stage apoptotic cells shown in white, and the data for the late-stage 
apoptotic/necrotic cells shown in grey) versus the total number of cells. Data represent the mean ± SEM of three different experiments. The 
significance of the differences was determined with a one-way ANOVA with Bonferroni post-test: ** p<0.01 vs. control.
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represent a proper way to improve GBM treatment 
outcome.
GBM treatment is an undisputed neurosurgical 
challenge. The major limitations of the current anti-
proliferative therapies for GBM are related to the onset 
of drug resistance phenomena [5]. Results from both 
basic and clinical research have suggested that the 
development of irreversible agents [12, 19] and multi-
target compounds [9] may lead to the discovery of novel 
therapeutic strategies for GBM and other types of solid 
tumours. In terms of current multi-therapy strategies, 
dual PI3K/mTOR inhibitors are emerging in GBM. 
Several inhibitors targeting these two kinases have been 
developed; for example, XL765 has been demonstrated to 
reduce cell viability in vitro and is possibly effective when 
combined with TMZ therapy [33]. Recently, we identified 
new reversible compounds dual-targeting MDM2 and 
TSPO, two proteins that are both up-regulated in GBM 
so contributing to cancer cell resistance to physiological 
apoptosis [25]. These compounds have showed high and 
prolonged anti-proliferative activity in GBM cells, with 
significantly higher effects than those elicited by the 
single target reference standards, thus confirming that 
dual inhibitors might have improved results compared to 
monotherapy.
Furthermore, it is also true that targeting one or 
more signalling pathways with reversible molecules may 
be not enough to sustain the therapeutic effects over time, 
and actually may favour the activation of alternative 
signalling pathways and the onset of drug resistance 
phenomena. Recently, there has been a resurgence of 
interest towards irreversible inhibitors, and this topic has 
been excellently reviewed in several publications from a 
risk-benefit perspective [34, 35] and in terms of the current 
irreversible inhibitors that are in preclinical or clinical 
development [36]. Several tyrosine kinase inhibitors 
with irreversible activity have been developed, and some 
of these are now in phase I-III trials for the treatment of 
different solid tumours, [37-40] including GBM. The 
irreversible inhibitors include Canertinib (CI1033; Pfizer/
Warner-Lambert), Pelitinib (EKB-569; Wyest-Ayerst) and 
Dacomitinib [41]. 
Based on this evidence, we wondered whether 
a molecule that modulated two distinct intracellular 
targets (namely MDM2 and TSPO) with a long-lasting 
mechanism of action, might have greater and longer life 
span of anti-proliferative activity in GBM cells.
In the design of the new irreversible dual target 
compound, the basic structure of the recently developed 
2-phenylindol-3ylglyoxyldipeptide derivative EB54, [25] 
was examined to determine the best synthetically feasible 
position for the introduction of a moiety conferring 
long-lasting properties. The 5-position of the indole ring 
seemed suitable for a chemo-reactive group. Among 
possible chemo-reactive moieties, isothiocyanate has 
proven extremely versatile as an electrophilic moiety for 
long-lasting ligands. It can easily be synthesized from a 
primary amino group; furthermore, its high reactivity 
towards amino and sulfhydryl groups, along with its low 
reactivity towards water and other hydroxyl functions, 
accounts for its successful applications in receptor studies 
[26, 42]. Actually, we recently employed this moiety to 
develop selective irreversible TSPO ligands as useful 
tools to study the role of this protein in human GBM cells 
[26, 43]. Thus, the derivative EB148 was synthesized and 
biologically evaluated. 
Compound EB148 was able to cause GBM cell 
death by arresting the cell cycle and inducing an apoptotic 
pathway of cell death. The effects elicited by EB148 
appeared to be greater and more long-lasting than those of 
the reversible analogue. Furthermore, the apoptotic effects 
appeared to be irreversible so that the cells were not able 
to regain proliferative activity after drug wash-out. 
The biological characterization of EB148 started 
with the evaluation of its ability to bind TSPO and to 
induce ∆ψm collapse in mitochondria isolated from 
GBM cells. The compound displayed a nanomolar range 
affinity for TSPO, with a long-lasting binding profile, 
as demonstrated by kinetic competition experiments. 
Through TSPO activation, EB148 induced permeability 
transition pore opening in GBM cells without any 
steroidogenic activity and, differently to that which 
occurred with the reversible analogue EB54, this effect 
was maintained over time, even after cell wash-out. 
Therefore, we can conclude that the long-time activation 
of TSPO caused an irreversible mitochondrial collapse.
Then, the ability of the same compound to dissociate 
the MDM2-p53 complex was investigated by an in 
vitro ELISA-based assay [25]. To evaluate the covalent 
mechanism of action, kinetic dissociation studies of p53-
MDM2 complex inhibition were performed both in cell 
lysates and in whole cells. EB148 inhibited MDM2-p53 
association with a nanomolar potency, a value comparable 
to that detected with the reversible analogue EB54. As 
a major difference, the long-lasting compound EB148 
induced prolonged inhibition of the MDM2-p53 complex 
that was maintained even after cell wash-out, thus 
demonstrating its covalent binding to MDM2 protein. The 
sustained inhibition of MDM2-p53 complex formation 
may account for the different kinetic pattern in the 
regulation of p53 gene targets induced by the reversible 
versus the long-lasting compound and may explain the 
differences in the long-term pro-apoptotic effects elicited 
by EB148. To dissect the molecular mechanism involved 
in the long-term effects of EB148, the modulation of ERKs 
was investigated. The GBM biological characteristics 
are exemplified by prominent proliferation, active 
invasiveness and rich angiogenesis. These features are 
mainly due to highly deregulated signalling pathways in 
the tumour, in particular the Ras/MEK/MAPK pathways 
[44].
MAPK signalling plays a crucial role in almost all 
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cell functions and therefore requires exquisite control of its 
spatiotemporal activity [45]. Depending on the duration, 
the magnitude and its subcellular localization, ERK 
activation controls various and opposite cell responses, 
such as proliferation, migration, differentiation and death. 
An interesting question is how such an apparently 
straightforward and simple cascade can generate a wide 
array of biological responses depending on the cellular 
context. One way to achieve diversity in signalling 
outcomes is to control the signal duration by acting on 
the dose and on the drug-target residence time. Indeed, 
limiting exposure to ligands could be another mechanism 
to control signalling duration and switch-like cellular 
responses [46, 47]. 
The proliferative effects of ERKs in response to 
mitogenic signals are commonly associated with a transient 
activation of these kinases. In contrast, a sustained ERK 
activation induces a progressive accumulation of death-
promoting factors, up to a level that induces cell death. 
Prolonged ERK activation has been shown to promote 
death of human cancer cell lines of different origins 
and to be the primary mechanism of action of different 
chemotherapy agents [48-53]. Understanding the critical 
pathological roles of this signalling molecule and its 
regulatory mechanisms in the progression of glioma is 
important for the development of effective molecular-
targeted therapies against GBM. Furthermore, the 
development of ERK signalling modulators may likely 
represent a smart strategy to selectively target cancer cells 
with deregulated ERK activity but not normal cells in 
which ERK activation is transient.
In several tumour cell lines, a strict interplay 
between ERK signalling and the MDM2-p53 pathway has 
been demonstrated. ERK, via a phophorylation process, 
promotes p53 stability and activity and inhibits p53 
interaction with MDM2. On the other hand, p53 may act 
as an upstream regulator of ERK activation for the drug-
mediated induction of apoptosis in different tumour cells 
[46, 48, 51]. Notwithstanding that the role of the p53-
MDM2 axis in the progression of GBM has been well 
explained, the interplay between p53-MDM2 and the ERK 
pathway has not yet been deeply investigated. 
In this study, EB148 was demonstrated to induce 
a sustained and p53-dependent stimulation of ERK1/2 
phosphorylation, whereas no significant activation was 
detected after treatment of cells with the reversible 
analogue, EB54. Because of prolonged ERK activation, 
EB148 favoured the association of MDM2 with ERK. 
Because it has been demonstrated that ERK mediated 
MDM2 phosphorylation reduced the ubiquitin ligase 
activity of MDM2 and in turn potentiated p53 pro-
apoptotic effects, we can speculate that EB148, favouring 
MDM2-ERK association, contributed to sustain p53 
activation over time. In this scenario, the long-lasting 
inhibition of MDM2 may activate a feed-back mechanism 
through which the p53-MDM2-ERK axis feeds itself in 
the control of cell fate triggering an irreversible path of 
cell death.
Overall, our data demonstrated that in GBM cells 1) 
EB148 acts as a dual and irreversible-like ligand targeting 
both MDM2 and TSPO proteins, 2) the long-lasting 
activation of the two targets induced irreversible apoptosis, 
and 3) the ERK pathway is likely one of the molecular 
mechanism involved in the p53-mediated effects.
MATERIAL AND METHODS
Reagents and cells
The human glioblastoma multiforme U87MG 
cells were obtained from the National Institute for 
Cancer Research of Genova (Italy) and monitored 
for DNA profiling. Propidium iodide (PI) and the 
fluorescent dye, 5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) 
were obtained from Molecular Probes, Invitrogen, 
Milan, Italy. The 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay kit was from Promega Italia, 
Milan, Italy. The RNeasyH Mini Kit was from Qiagen, 
Milan, Italy and the ProtoScriptH cDNA Synthesis Kit 
was obtained from Biolabs, Euroclone, Milan, Italy. 
Chemical synthesis
General directions. A Reichert Kofler hot-stage 
apparatus was used to determine the melting points, that 
are uncorrected. For routine nuclear magnetic resonance 
spectra, compounds were dissolved in DMSO-d6 and a 
Bruker operating at 400 MHz was utilized. Analytical 
TLC was carried out on Merck 0.2 mm precoated silica 
gel aluminum sheets (60 F-254).
N-Boc-L-leucine-L-phenylalanine ethyl ester 2, 
[25] L-leucine-L-phenylalanine ethyl ester 3, [25] 5-nitro-
2-phenylindole 5, [26] and 5-nitro-(2-phenylindol-3-yl)
glyoxyl chloride 6 [26] were prepared in accordance with 
our previous works.
(5-Nitro-2-phenylindol-3-yl)glyoxyl-L-leucine-L-
phenylalanine ethyl ester 7. Oxalyl chloride (0.43 ml, 
5.0 mmol) was added dropwise, at 0°C, to a well-stirred 
mixture of the 5-nitro-2-phenylindole 5 (2.5 mmol) in 
freshly distilled diethyl ether (10 ml). The mixture was 
maintained at room temperature for 12 h. The precipitate 
was collected by vacuum filtration to give the acyl chloride 
6 that was directly used in the subsequent reaction. A 
solution of compound 3 (0.360 g, 1.09 mmol) in 5 ml of 
dry toluene was added dropwise to a stirred suspension, 
cooled at 0°C, of the 5-nitro-2-phenylindol-3-ylglyoxylyl 
chloride 6 (1.23 mmol) in 15 ml of the same solvent, 
followed by the addition of a solution of triethylamine 
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(0.18 ml, 1.31 mmol) in 1.5 ml of dry toluene. The 
reaction mixture was left under stirring overnight at 
room temperature (TLC analysis) and then filtered. The 
collected precipitate was washed with a 5% NaHCO3 
aqueous solution and collected again to give a first 
portion of crude product. The toluene was removed under 
reduced pressure and the residue dissolved with CH2Cl2. 
The organic solution was washed with diluted HCl, a 5% 
NaHCO3 aqueous solution and water, dried (MgSO4), and 
evaporated to dryness to yield an additional amount of 
crude product. Compound 7 was finally purified by flash-
chromatography (AcOEt: hexane = 4:6 as eluent). Yield 
74%; mp = 110-112°C. 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 0.82 (d, J = 6.36 Hz, 6H); 1.06 (t, J = 7.2 Hz, 3H); 
1.22-1.29 (m, 1H); 1.36-1.49 (m, 2H); 2.96-2.99 (m, 2H); 
3.97 (q, J = 7.0 Hz, 2H); 4.15-4.22 (m, 1H); 4.43-4.47 (m, 
1H,); 7.22-7.28 (m, 5H); 7.45-7.47 (m, 3H); 7.62-7.65 (m, 
2H); 7.68 (d, J = 8.8 Hz, 1H); 8.18 (dd, J = 9.2 Hz, J = 2.4 
Hz, 1H); 8.45 (d, J = 7.2 Hz, 1H, exch. with D2O); 8.74 (d, 
J = 8.4 Hz, 1H, exch. with D2O); 8.92 (d, J = 2.4 Hz, 1H); 
13.00 (bs, 1H, exch. with D2O).
(5-Amino-2-phenylindol-3-yl)glyoxyl-L-leucine-
L-phenylalanine ethyl ester 8. A mixture of (5-nitro-2-
phenylindol-3-yl)glyoxyl-L-leucine-L-phenylalanine 
ethylester 7 (0.200 g, 0.33 mmol) and 10% Pd/C (0.050 g) 
in 150 ml of absolute ethanol was hydrogenated at room 
temperature. Once hydrogen absorption ceased (3-4 h), the 
catalyst was filtered off and the solvent was evaporated. 
Compound 8 was finally purified by flash-chromatography 
(AcOEt: hexane = 6:4 as eluent). Yield 71%; mp = 98-
100°C; 1H NMR (400 MHz, DMSO-d6) δ (ppm): 0.79 (d, 
J = 6.4 Hz, 6H); 1.06 (t, J = 7.2 Hz, 3H); 1.11-1.15 (m, 
1H); 1.32-1.44 (m, 2H); 2.90-3.02 (m, 2H); 3.97-4.05 (m, 
3H); 4.43-4.47 (m, 1H); 4.87 (bs, 2H, exch with D2O); 
6.61 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H); 7.16 (d, J = 8.8 Hz, 
1H); 7.20-7.23 (m, 3H); 7.26-7.29 (m, 2H); 7.34-7.38 (m, 
4H); 7.49 -7.51 (m, 2H); 8.33 (d, J = 7.2 Hz, 1H, exch 
with D2O); 8.41 (d, J = 8.8 Hz, 1H, exch with D2O); 11.92 
(bs, 1H, exch with D2O).
5-[N-(5-Isothiocyanato-2-phenylindol-3-yl)
glyoxyl-L-leucine-L-phenylalanine ethyl ester EB148. A 
stirred solution of 8 (0.200 g, 0.35 mmol) in 20 ml of 6% 
NaHCO3 was added to 20 ml of CH2Cl2. After 20 min, 
thiophosgene (0.03 ml, 0.35 mmol) was added dropwise 
at 0 °C. The reaction mixture was stirred overnight. The 
aqueous phase was then extracted with CH2Cl2 and the 
resulting organic layer was dried over MgSO4. The product 
was finally purified by flash chromatography (Hexane: 
AcOEt = 6:4 as eluent). Yield 62%; mp = 93-95°C. 1H 
NMR (400 MHz, DMSO-d6) δ (ppm): 0.84 (d, J = 6.4 Hz, 
6H); 1.07 (t, J = 7.2 Hz, 3H); 1.24-1.33 (m, 1H); 1.36-1.51 
(m, 2H); 2.97-3.01 (m, 2H); 3.99 (q, J = 7.2 Hz, 2H); 4.17-
4.23 (m, 1H); 4.48-4.53 (m, 1H); 7.21 -7.24 (m, 5H); 7.34 
(dd, J = 8.4 Hz, J = 2.0 Hz, 1H); 7.43-7.46 (m, 3H); 7.54 
(d, J = 8.4 Hz, 1H); 7.60- 7.62 (m, 2H); 7.95 (d, J = 2.0 
Hz, 1H); 8.43 (d, J = 7.2 Hz, 1H, exch with D2O); 8.68 (d, 
J = 8.4 Hz, 1H, exch with D2O); 12.67 (bs, 1H, exch with 
D2O). 
13C NMR (100 MHz, DMSO-d6) δ (ppm): 14.32; 
22.60; 23.17; 24.43; 37.14; 41.40; 51.07; 54.03; 60.90; 
109.46; 113.91; 118.49; 121.78; 124.63; 126.98; 128.10; 
128.67; 129.53; 129.94; 130.09; 131.33; 135.07; 137.42; 
149.09; 165.94; 171.65; 171.69; 186.77. 
Stability test
To test the stability of EB148 in aqueous solution, 
the compound was dissolved in DMSO and diluted with 
PBS to the final 1 µM concentration (the amount of 
DMSO in the final solution was 1%). The solution was 
maintained in a closed vial and analysed by HPLC at 
specific times (4, 8, 24, 48 and 72 h) using the following 
conditions: column Shim-pack VP-ODS 4.6 µm (250 mm 
x 4.6 mm), isocratic elution with water, flow rate of 1 ml/
min, room temperature. The percentage of decomposition 
was calculated on the base of peak area of the product.
Cell cultures
U87MG cells were cultured in RPMI medium 
supplemented with 10% FBS, 2 mM-glutamine, 100 U/
ml penicillin, 100 mg/ml streptomycin and 1% non-
essential amino acids at 37°C in 5% CO2. U87MG cells 
were plated at 5x103 cells/cm2. After 24 h, culture medium 
was replaced with fresh medium containing newly 
synthesized compounds solubilized in DMSO for the 
indicated incubation times. DMSO was added to control 
cells (0.5 % v/v). Human MSCs were cultured in normal 
growth medium (MSCGM, Lonza), plated (5x103 cells/
cm2) in 75-cm2 flasks and incubated at 37 °C in 5% CO2 
and 95% air. The medium was changed to remove non 
adherent cells every 3 to 4 days, and the cells were used 
at passages 0 to 3.
TSPO binding assays
Equilibrium radioligand binding assays were 
performed essentially as previously described [54]. 
Briefly, aliquots of U87MG cell membranes (20 µg of 
proteins) were incubated with [3H]PK 11195 (1.5 nM) 
in the presence (non-specific binding) or in the absence 
(total binding) of unlabelled PK 11195 (1 µM), in the 
final volume of 500 µl of assay buffer for 120 min at 
0°C. Samples were rapidly filtered under vacuum through 
GF/C glass fiber filters. Radioactivity was measured by 
liquid scintillation counter (TopCount; PerkinElmer Life 
and Analytical Sciences; 65 % counting efficiency). 
In U87MG cell membranes, [3H]PK11195 maximum 
number of binding sites (Bmax) and affinity (Kd) were 
determined in previous experiments by Scatchard analysis 
of saturation binding data [43].
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TSPO association and dissociation kinetics
Association kinetics for [3H]PK11195 were 
determined incubating U87MG cell membranes (20 μg 
protein) with 1.5 nM radioligand at various time points 
up to a total of 3 h. Dissociation kinetics were determined 
by pre-equilibrating membranes and [3H]PK11195 for 
120 min and the adding a saturating concentration of cold 
PK11195 (1 μM).
Association and dissociation rate constants for [3H] 
PK11195 binding were determined by global analysis of 
the association and dissociation binding curves according 
to mono-exponential association and decay curves. 
From this analysis an estimate of the dissociation (koff) 
and observed association (kobs) rates for ligand binding 
was generated; the association rate constant (kon) was 
determined according to the following relationship kobs 
= [A] kon + koff; ligand-receptor half-life was calculated 
as 0.693/koff. 
For competition kinetics, the [3H] PK11195 curves 
in the presence and absence of EB54 or EB148, were fitted 
using the equations in Dowling and Charlton [55].
Mitochondrial membrane potential (∆ψm) 
dissipation analysis
The ∆ψm dissipation was assessed using the 
fluorescent dye 5,59,6,69-tetrachloro1,19,3,39-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) [25]. 
Mitochondria were isolated from U87MG cells using the 
Mitochondria Isolation Kit (Sigma Aldrich, Milan, Italy) 
following manufacturer’s instructions. 
Isolated mitochondria were treated for 20 min 
with EB54 or EB148 (1 µM). In wash-out experiments, 
mitochondria were then centrifuged at 11.000 x g for 5 
min, washed with fresh saline and suspended in JC-1 
buffer not containing the drugs. At the end of treatments, 
5 µg of control and treated mitochondria were added to 
the JC-1 dye. The fluorescence (relative fluorescence 
units, RFU) of the sample was read in a spectrofluorimeter 
using a time-drive method (one acquisition each 10 sec, 
for 10 min), where the excitation wavelength was set to 
490 nm and emission wavelength at 590 nm. JC-1 exhibits 
potential-dependent accumulation in mitochondria, 
where higher concentrations start to form J-aggregates 
indicated by a fluorescence emission shift from green 
(529 nm, monomer emission maximum) to orange-red 
(590 nm, aggregate emission maximum). Consequently, 
mitochondrial depolarization is indicated by a decrease in 
the orange-red fluorescence intensity.
Dissociation studies of native MDM2/p53 complex
To test the ability of new compound to dissociate 
the native MDM2/p53 complex, a quantitative sandwich 
immune-enzymatic assay, on crude cell lysates obtained 
from U87MG cells was applied [25,29]. Cells were 
washed twice in ice-cold phosphate-buffered saline, 
collected by centrifugation, and suspended in lysis buffer 
(20 mM Tris HCl, 137 mM NaCl, 10% glycerol, 1% 
NONIDET40, 2 mM EDTA, pH 8) containing 1% of the 
Protease inhibitor Cocktail (Sigma Aldrich, Milan, Italy). 
96-wells were pre-coated with a mouse full-length anti-
MDM2 antibody (sc-965, Santa Cruz Biotechnology, 
1:50 in 0.05% Poly-L-Ornithine) overnight at room 
temperature. Cell lysates (20 µg in a final volume of 100 
µl) were pre-incubated with DMSO (control), or different 
compound concentration for 10 min at room temperature, 
and then transferred to the pre-coated wells for 60 min. 
After three quick washes with PBS/Tween 0.05% to 
remove unbound MDM2, each well was incubated for 15 
min with 1% BSA, to block nonspecific sites, and then for 
1.5 h at room temperature with a rabbit primary anti-p53 
antibody (sc-6243, Santa Cruz Biotechnology, 1:250). 
Then, wells were washed and incubated for 1 h with an 
anti-rabbit HRP-conjugate antibody, and washed again. 
The TMB substrate kit (Thermo Fisher Scientific) allowed 
a colorimetric quantification of the MDM2/p53 complex. 
Blanks were obtained processing cell lysates in the 
absence of the primary anti-p53 antibody. Absorbance’s 
values at 450 nm were measured, background subtracted 
and sigmoid dose-response curves were generated using 
Graph Pad Prism 4 software, from which IC50 values of 
MDM2/p53 complex were derived.
EB148 binding to MDM2: association and 
dissociation kinetics
To investigate the association kinetics of the 
compounds to human MDM2, 20 µg of U87MG cell 
lysates, suspended in lysis buffer, were incubated for 
different times (0-120 min) with EB148 or EB54. 
Following incubation, cell lysates were captured on wells 
pre-coated with MDM2 antibody for an additional 60 min. 
After extensive washes, levels of the MDM2/p53 complex 
were quantified as described above. 
In dissociation studies, U87MG cell lysates, 
suspended in lysis buffer, were incubated for 90 min with 
EB148 or EB54 in order to reach association plateau. 
Dissociation was initiated by the addition of 20 volumes 
of cold buffer, and lysates were further incubated at 4°C 
for the indicated times (0-180 min). Following incubation, 
200 µl of the mixture were captured on wells pre-coated 
with MDM2 antibody for an additional 60 min. After 
extensive washes, levels of the MDM2/p53 complex were 
quantified as described above. 
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Quantitation of p53/MDM2 and ERK/MDM2 
complexes in U87MG cells
U87MG cells were treated with DMSO (control), 
EB148 or EB54 for different times. When indicated, after 
8 h of incubation, cells were washed twice with fresh 
saline and cultured in drug-free medium for an additional 
24 h. At the end of the treatment period, the cells were 
collected, and suspended in lysis buffer containing 1% 
of the Protease inhibitor Cocktail. Levels of p53/MDM2 
or ERK/MDM2 complexes were quantified using the 
ELISA test method described above in wells pre-coated 
with an anti-MDM2 antibody. Cell lysates (20 µg in a 
final volume of 100 µl) were transferred to the pre-coated 
wells for 60 min; each well was then incubated for 1.5 h 
at room temperature with p53 or ERK (sc-7383 SantaCruz 
Biotechnology, 1:500) primary antibodies.
Relative mRNA quantification of p53 target genes
The assessment of the levels of p53 mRNA gene 
targets was evaluated by real-time reverse transcription 
polymerase chain reaction (real-time RT-PCR). In brief, 
total RNA was extracted from control cells as well 
as from cells treated with EB148 or EB54 (1 µM) for 
different times (8 h, 16 h or 24 h), using RneasyH Mini Kit 
(Qiagen, Hilden, Germany), according to manufacturer’s 
instructions. cDNA synthesis was performed with 500 ng 
of RNA using using i-Script cDNA synthesis kit (BioRad, 
Hercules, USA). RT-PCR reactions consisted of 25 µl 
FluocycleH II SYBRH (Euroclone, Milano, Italy), 1.5 µl 
of both 10 µM forward and reverse primers (listed in [56]), 
3 µl cDNA, and 19 µL of H2O. For each sample, mRNA 
levels of p53 gene target were normalized against β-actin 
mRNA levels, and relative expression was calculated by 
using Ct value. PCR specificity was verified by both the 
melting curve analysis and gel electrophoresis.
Western blotting analysis
U87MG were treated with DMSO (control), 
EB148 or EB54 for 16 h. When indicated, after 16 h of 
incubation, cells were washed twice with fresh saline, 
and incubated with fresh medium not containing the 
drugs for an additional 24 h. At the end of the treatment 
period, the cells were collected and then lysed for 60 min 
at 4 °C using 200 μl of RIPA buffer (9.1 mM NaH2PO4, 
1.7 mM Na2HPO4, 150 mM NaCl, pH 7.4, 0.5% sodium 
deoxycholate, 1% Nonidet P-40, 0.1% SDS, and a 
protease-inhibitor cocktail). Equal amounts of the cell 
extracts (40 µg of protein) were diluted in Laemmli sample 
solution, resolved using SDS-PAGE (8.5%), transferred to 
PVDF membranes and probed overnight at 4 °C using an 
anti-p53 antibody (FL-393, Santa Cruz Biotechnology; 
1:500). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was the loading control (G9545, Sigma 
Aldrich, Milan, Italy, 1:5000). The primary antibodies 
were detected using the appropriate peroxidase-conjugated 
secondary antibodies, which were then detected using 
a chemioluminescent substrate (ECL, Perkin Elmer). 
Densitometric analysis of the immunoreactive bands was 
performed using Image J Software. 
Cell viability and proliferation assay
The effects of compound treatment on U87MG cell 
viability and proliferation were evaluated by Trypan blue 
exclusion assays and MTS assay, respectively. U87MG 
cells were treated with EB148 or EB54 for 72 h. Following 
treatment, harvested cells were mixed with an equal 
volume of 0.4% trypan blue dye. For quantization of cell 
viability, blue and bright cells were counted, and viability 
was calculated as the number of living (bright) and dead 
(blue) cells in each well. To establish the effect of MDM2 
inhibitors on cell proliferation, cells were treated for 72 h 
with different concentrations of each compound (0.1 nM–
100 µM) for 72 h, and then MTS assay was performed 
according to the manufacturer’s instructions.
The absorbance of formazan at 490 nm was 
measured in a colorimetric assay with an automated plate 
reader (Victor Wallac 2, Perkin Elmer). For wash-out 
experiments, U87MG cells were treated with EB148 or 
EB54 (100 nM-10 µM) for 72 h. Following incubation, 
medium-containing drugs was replaced by fresh medium, 
and cells were allowed to growth for the indicated days. 
At the end of treatments, cell proliferation was measured 
by MTS assay. The results were calculated by subtracting 
the mean background from the values obtained from each 
evaluation and were expressed as the percentage of the 
control (untreated cells). Sigmoid dose-response curve 
was generated, from which the IC50 values were derived.
To evaluate compound toxicity, MSCs were treated 
for 72 h with different concentrations of EB148 or EB54. 
At the end of treatments, cell proliferation was measured 
by MTS assay.
Cell cycle analysis
The measurement of the percentage of cells in 
the different phases of cell cycle was performed using 
the MuseTM Cell Analyzer (Merck KGaA, Darmstadt, 
Germany). Briefly, U87MG cells were treated for 24 
h with DMSO, reversible or irreversible compound (1 
µM). Adherent cells were collected and suspended in the 
fluorescent reagent (MuseTM Cell Cycle reagent). After 
incubation for 30 min at room temperature in the dark, the 
measurements of the percentage of cells in the different 
phases was acquired [25].
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Annexin V and 7-AAD staining
Dual staining with Annexin V coniugated to 
fluorescein-isothiocyanate (FITC) and 7-amino-
actinomysin (7-AAD) was performed using the 
commercially available kit (Muse Annexin V and Dead 
Cell Kit; Merck KGaA, Darmstadt, Germany).
U87MG cells were treated with DMSO (control), 
EB54 or EB148 (1 µM) for 24 h. Both floating and 
adherent cells were collected, and incubated for 10 min 
at room temperature with the fluorescent reagent. After 
incubation, the percentages of living, apoptotic and 
dead cells were acquired and analyzed by MuseTM Cell 
Analyzer in accordance to the manufacture’s guidelines 
[25].
Statistical analyses
The nonlinear multipurpose curve-fitting program 
Graph-Pad Prism (GraphPad Software Inc., San Diego, 
CA) was used for data analysis and graphic presentations. 
All data are presented as the mean ± SEM. Statistical 
analysis was performed by one-way analysis of variance 
(ANOVA) with Bonferroni’s corrected t-test for post-
hoc pair-wise comparisons. P < 0.05 was considered 
statistically significant.
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